Burning Rock Biotech Ltd. BNR

What this company does

Burning Rock Biotech Ltd offers NGS-based cancer therapy selection test products used to assist physicians in selecting therapy for cancer patients. It recognized revenues of RMB515.8 million and RMB539.6 million (US$77.2 million) in 2024 and 2025, respectively. Its commercial infrastructure consists of both a central laboratory model and an in-hospital model. Under the central laboratory model, tissue and liquid biopsy samples are delivered to its central laboratory in Guangzhou for processing, and it issues test reports generally within six days of receipt, 25 days for MRD products and nine days for early detection products. Its central laboratory has a designed annual capacity of approximately 100,000 tests. It has GMP-standard manufacturing facilities in Guangzhou for the manufacturing of its reagent kits, with an aggregate designed annual production capacity of up to 600,000 kits. In 2016 it began offering an in-hospital model, providing turn-key solutions to address Chinese hospitals' challenges in adopting NGS-based cancer therapy selection. As of December 31, 2025, it had partnered with 94 hospitals in 43 cities across China under this model.

Written from the business description in Burning Rock Biotech Ltd's annual report to the U.S. Securities and Exchange Commission, filed 28 April 2026. Every sentence was checked against that document before publication.